52 results about "Management of heart failure" patented technology

The present invention provides a drug for at least one of prevention and treatment of cardiac failure capable of suppressing cardiac depression and the onset of cardiac failure in ventricular remodeling, and a method for screening the drug. The drug for at least one of prevention and treatment of cardiac failure of the present invention contains a compound that inhibits a functional expression of ASK1 protein in a cardiomyocyte as an active ingredient, and a method for screening a drug for at least one of prevention and treatment of cardiac failure of the present invention includes selecting a medicinal component for at least one of prevention and treatment of cardiac failure from a drug candidate compound by using inhibition of a functional expression of ASK1 protein as an indication. As shown in FIG. 1, if ASK1 protein is removed, for example, the ventricle dilation can be attenuated in ventricular remodeling after myocardial infarction, pressure loading, or the like, which makes it possible to prevent and treat cardiac failure.

The present invention relates to the identification of miRNAs that are involved in heart failure and the process of post-myocardial infarction remodeling in heart tissue. Modulation of these identified miRNAs as a treatment for myocardial infarction, cardiac remodelling, and heart failure is described.

Devices and methods of use identification, treatment, and/or management of heart failure and/or associated conditions. Methods may include providing a baroreflex therapy system including a blood pressure sensor and a heart rate sensor, providing an implantable measurement device proximate a blood vessel of a patient, the implantable measurement device including an electrode, providing a control system coupled to the baroreflex therapy system and the implantable measurement device, the control system programmed to automatically determine an impedance of the blood vessel with the implantable measurement device over a time period of at least one cardiac cycle, determine arterial stiffness of the blood vessel based on the impedance, determine blood pressure and heart rate, and activate, deactivate or otherwise modulate the baroreflex therapy system to deliver a baroreflex therapy based on the blood pressure, heart rate and arterial stiffness.

The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be used to repress fast fiber genes and activate slow fiber genes in the treatment of musculoskeletal disorders. Inhibition of miR-499 and/or miR-208b is proposed as a treatment for cardiac hypertrophy, myocardial infarction, and/or heart failure. Pharmaceutical compositions comprising antagonists and agonists of miR-499 and miR-208b function are also disclosed.

The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2 and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of class II HDAC's has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides the link between MEF-2 and class II HDAC's, a kinase known as PKD. The present invention further demonstrates that inhibitors of PKD inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression and cellular reorganization that occurs when MEF-2 dependent transcription is inhibited.

The invention relates to a traditional Chinese pharmaceutical composition for treating cardiac failure and process for preparation, wherein the composition is prepared from the following medicinal raw materials (by weight portion): red ginseng 338-413 parts, monkshood 1013-1238 parts, poria cocos wolf 1013-1238 parts, lepidium seed 675-825 parts, notoginseng 563-688 parts, ophiopogon root 675-825 parts, the preparing process comprises mixing red ginseng, prepared aconite root, poria cocos, lepidium seed, notoginseng and ophiopogon root, charging water, grilling twice, merging the grilling liquid and filtering, concentrating the filtrate to clear grease with specific gravity of 1.07-1.10/60 Deg C, spray drying the clear grease, charging medicinal auxiliary materials, pelleting or packing capsules or making granules.

The invention provides a method for treating or preventing heart failure in a subject, which includes administering to the subject in need thereof a therapeutically effective amount of a Poloxamer (e.g., Poloxamer 188).

There is currently no completely effective treatment for heart failure. Considering the need for, and current void in the medical field for, a treatment for heart failure, the invention is drawn to treating heart failure. In particular aspects, the invention is drawn to the discovery that certain polyunsaturated fatty acids (PUFAs) and doses thereof are useful for treating heart failure. In other particular aspects, the invention is drawn to the discovery that certain PUFAs and doses thereof are useful for preserving mitochondrial function in a heart failure subject.

The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2 and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of class II HDAC's has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between MEF-2 and class II HDAC's, a kinase known as PRK. The present invention further demonstrates that inhibitors of PRK inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression and cellular reorganization that occurs when MEF-2 dependent transcription is activated.

The invention relates to a fluorescent probe for detecting nitroxyl (HNO), in particular to a bodipy compound and application thereof. The bodipy compound is as shown in general formula I and serves as the fluorescent probe for HNO. The corresponding fluorescence intensity of the compound serving as the fluorescent probe for HNO is varied in the presence of HNO, and the compound can be used for HNO detection, can greatly reduce the interference of external detection conditions and improve detection accuracy. The compound serving as the fluorescent probe can be used for detecting the level of HNO inside and outside cells, not only is of great scientific significance for illuminating the HNO intracellular in-situ generation mechanism, but also lays the theoretical basis for discovering new drugs for treating cardiac failure, and provides feasible selection for cardiac failure treatment. The general formula I is as follows.

The present invention relates to diagnostic means and methods. Specifically, the present invention encompasses a method of diagnosing the cause of cardiac necrosis in a subject comprising determining the amount of a cardiac troponin and the amount of a BNP-type peptide in a sample from a subject suffering from cardiac necrosis and comparing the amount of the cardiac troponin and the amount of the BNP-type peptide to reference amounts, whereby the cause of the cardiac necrosis is to be diagnosed. The present invention further relates to a method of determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against initial heart failure and to a method for determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against coronary heart disease. Also encompassed are diagnostic uses, devices, and kits.

Myocardial hypertrophy is a pathological change of a plurality of kinds of angiocardiopathy. The main mode is the heart remodeling comprising cardiac muscle cell hypertrophy and change of the interstitial tissue component mainly. In the present invention, the nitrate medicine is used in treatment for myocardial hypertrophy caused by various reasons and excellent therapy effect is obtained. Currently the nitrate medicine is extensively applied in treatment for the coronary heart disease, the heart colicky pain and heart failure. Preload of the heart and myocardial consumption of oxygen are reduced by extension of the venous system. The drugs used in clinical field currently comprise Nitroglycerin, Amyl Nitrite, dicho nitric acid sorbite, sorbide dinitrate, 5-isosorbide dinitrate, Nitroglycerin, pentanitrol ters and itramine tosylate.

Provided are novel compound that is useful as a treatment agent or a prophylactic agent for cardiac failure, cardiac failure due to dystelectasis, left ventricular diastolic impairment, angina or cardiac infarct, hypertension, ischemic cardiac disease, and myocardial relaxation impairment recognized in cardiac failure, atrial fibrillation or ventricular arrhythmia, and a pharmaceutical composition containing the same. The invention pertains to a 1,4-benzothiazepine-1-oxide derivative represented by general formula [I] (In the formula, R represents a hydrogen atom or a hydroxyl group.) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same [I].

The present invention relates to a method of treating congestive heart failure (CHF) in a subject comprising administering a peptide derived from atrial natriuretic peptide (ANP) prohormone (eg vessel dilator; VSDL) or a mimetic thereof. In a particular application, the invention provides a method of treating the particular indication known as acute decompensated congestive heart failure (ADCHF). Devices for intravenous or subcutaneous infusion for use in the method of the invention are also disclosed.

In the process of extensively searching for a drug elevating the survival ratio in ischemic heart failure, in particular postinfarction heart failure, it is found out that βARKct which is a βARK1 inhibitor is efficacious not only in improving heart function but also elevating survival ratio in postinfarction heart failure. Accordingly, it is expected that the βARK1 inhibitor is efficaciously usable as a remedy for ischemic heart failure which exerts not only an effect of improving heart function but also another effect of elevating survival ratio and, in its turn, contributes to the improved prognosis in patients with ischemic heart diseases.

The invention relates to a new crystal form of a sartan drug as well as a preparation method and application thereof, and belongs to the field of pharmaceutical chemicals. The invention discloses a sacubitril valsartan trisodium trihydrate eutectic composed of an angiotensin receptor antagonist and an enkephalinase inhibitor for treating hypertension or heart failure and a preparation method of the sacubitril valsartan trisodium trihydrate eutectic. The obtained crystal is analyzed by an X-ray powder diffraction spectrogram, and the characteristic absorption peaks 2 theta are located at 4.2 +/-0.2 degrees, 5.0 +/-0.2 degrees, 5.4 +/-0.2 degrees, 9.7 +/-0.2 degrees, 12.6 +/-0.2 degrees, 17.0 +/-0.2 degrees, 18.1 +/-0.2 degrees, 19.4 +/-0.2 degrees, 21.3 +/-0.2 degrees and 23.0 +/-0.2 degrees. The new eutectic crystal form disclosed by the invention is simple in preparation method, the crystal is easy to separate, and experiments show that the hygroscopicity and the stability of the neweutectic crystal form are superior to those of the existing eutectic crystal form, so that the new eutectic crystal form is favorable for being prepared into an oral solid preparation and processing and producing the oral solid preparation, and can be used for treating hypertension or heart failure.